• In March 2026, Glaukos Corporation announced the commercial launch of Epioxa, an incision-free, oxygen- and light-activated corneal cross-linking therapy for keratoconus, now available directly and via specialty distributors.
• By pairing this new therapy with expanded patient awareness, financial assistance, and access programs, Glaukos is aiming to tackle the long-standing underdiagnosis and undertreatment of this rare corneal disease.
• We’ll now examine how Epioxa’s incision-free keratoconus therapy and expanded patient access efforts interact with Glaukos’ existing investment narrative.

Uncover the next big thing with 31 elite penny stocks that balance risk and reward.

Glaukos Investment Narrative Recap

To own Glaukos, you need to believe in its shift from a single franchise toward a broader interventional ophthalmology platform, while accepting ongoing losses and reimbursement uncertainty. The Epioxa launch directly touches one key near term catalyst, the corneal health ramp, but also heightens execution risk around the Photrexa to Epioxa transition and payer adoption, which could be a meaningful swing factor for results over the next few years.

Among recent developments, the FDA approval of a repeat dosing protocol for iDose TR in January 2026 stands out alongside Epioxa. Together, repeatable iDose and an incision free cross linking option broaden Glaukos’ reach across chronic glaucoma and keratoconus care, but they also increase the company’s exposure to reimbursement decisions and the pace of physician training, both of which sit at the heart of the current catalyst and risk profile.

Yet behind this growth story, investors should be aware of how reimbursement pressure and slower than expected uptake could...

Glaukos' narrative projects $856.9 million revenue and $72.3 million earnings by 2028.

Uncover how Glaukos' forecasts yield a $134.79 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Some bullish analysts were modeling revenue of about US$923,000,000 and earnings near US$99,000,000 by 2028, which is far more optimistic than the baseline view that highlights reimbursement and launch execution risks. With Epioxa now commercial, you can weigh whether that faster growth scenario, or a more cautious path, feels closer to your own expectations.

Explore 4 other fair value estimates on Glaukos - why the stock might be worth 15% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Glaukos research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Glaukos research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Glaukos' overall financial health at a glance.

Searching For A Fresh Perspective?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.